CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016 and corporate highlights.
“We are very pleased with the progress of edasalonexent (CAT-1004) and the MoveDMD® clinical trial. We initiated the Phase 2 (Part B) portion of the trial in April. Interest in the trial and feedback on the trial design from the DMD community have been very positive,” said Jill C. Milne, Chief Executive Officer of Catabasis. “We also recently announced the initiation of an open-label extension for Part B of the trial based on acceptable safety and tolerability seen to date. The open-label extension is expected to provide additional data on safety and efficacy of edasalonexent when administered for up to 48 weeks and is an important part of our development strategy for edasalonexent in DMD. We believe we are developing edasalonexent in DMD in a rigorous way with double-blind, placebo-controlled trials, objective and quantifiable biomarker measures and multiple functional, strength and patient/proxy-reported measures. Assuming patient enrollment and trial conduct proceed as anticipated, we expect to report top-line safety and efficacy results from Part B, the placebo-controlled portion of the MoveDMD trial, in late 2016. We are building a pipeline of product candidates for rare diseases and our focus continues to be on our lead program edasalonexent in DMD.”
“We are very pleased with the progress of edasalonexent (CAT-1004) and the MoveDMD® clinical trial. We initiated the Phase 2 (Part B) portion of the trial in April. Interest in the trial and feedback on the trial design from the DMD community have been very positive,” said Jill C. Milne, Chief Executive Officer of Catabasis. “We also recently announced the initiation of an open-label extension for Part B of the trial based on acceptable safety and tolerability seen to date. The open-label extension is expected to provide additional data on safety and efficacy of edasalonexent when administered for up to 48 weeks and is an important part of our development strategy for edasalonexent in DMD. We believe we are developing edasalonexent in DMD in a rigorous way with double-blind, placebo-controlled trials, objective and quantifiable biomarker measures and multiple functional, strength and patient/proxy-reported measures. Assuming patient enrollment and trial conduct proceed as anticipated, we expect to report top-line safety and efficacy results from Part B, the placebo-controlled portion of the MoveDMD trial, in late 2016. We are building a pipeline of product candidates for rare diseases and our focus continues to be on our lead program edasalonexent in DMD.”
